184 328

Cited 1 times in

The effect of radiotherapy in liver-confined but non-resectable Barcelona Clinic Liver Cancer stage C large hepatocellular carcinoma

 Hong In Yoon  ;  Inkyung Jung  ;  Kwang-Hyub Han  ;  Jinsil Seong 
 ONCOTARGET , Vol.7(38) : 62715-62725, 2016 
Journal Title
Issue Date
Adolescent ; Adult ; Aged ; Aged, 80 and over ; Antineoplastic Agents/administration & dosage ; Carcinoma, Hepatocellular/mortality ; Carcinoma, Hepatocellular/radiotherapy* ; Carcinoma, Hepatocellular/therapy* ; Chemoembolization, Therapeutic ; Child ; Combined Modality Therapy ; Female ; Follow-Up Studies ; Humans ; Kaplan-Meier Estimate ; Liver/pathology ; Liver Neoplasms/mortality ; Liver Neoplasms/radiotherapy* ; Liver Neoplasms/therapy* ; Male ; Middle Aged ; Niacinamide/administration & dosage ; Niacinamide/analogs & derivatives ; Phenylurea Compounds/administration & dosage ; Propensity Score ; Registries ; Regression Analysis ; Republic of Korea ; Retrospective Studies ; Time Factors ; Treatment Outcome ; Young Adult
BCLC stage C ; large hepatocellular carcinoma ; median survival time ; propensity score matching ; radiotherapy
BACKGROUND AND AIMS: Clinical trials to determine the efficacy of radiotherapy (RT) in liver-confined but non-resectable Barcelona Clinic Liver Cancer (BCLC) stage C hepatocellular carcinoma (HCC) are scarce. We aimed to determine the benefit of RT in such tumors and investigated large HCC tumors. METHODS: HCC data from the Korea Central Cancer Registry recorded from 2008 to 2010 were used. A total of 593 patients met our inclusion criteria; 67 were treated with RT while the remainder made up the non-RT group. Fifty-two RT recipients underwent combination treatments within 4 weeks after the first RT treatment, and were defined as the combination RT group. We performed propensity score matching (PSM) to compare the RT or combination RT groups with the non-RT group. The endpoint was overall survival (OS). RESULTS: Median follow-up time for surviving patients was 48 months. After PSM, there was no difference in OS between the RT and non-RT groups or between the combination RT and non-RT groups. However, the combination RT group had a longer median survival time (MST) (10.7 vs. 6.9 months, respectively). Next, we conducted PSM between the combination RT and non-RT groups in patients with tumor sizes ≥10 cm; MST was significantly longer in the former group (10.1 vs. 5.4 months, respectively; bootstrap 95% confidence interval of the difference in MST: 0.2-11.8). CONCLUSIONS: As a combined modality, RT is a plausible therapeutic option for liver-confined but non-resectable BCLC stage C large HCC patients.
Files in This Item:
T201604275.pdf Download
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Biomedical Systems Informatics (의생명시스템정보학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Radiation Oncology (방사선종양학교실) > 1. Journal Papers
Yonsei Authors
Seong, Jin Sil(성진실) ORCID logo https://orcid.org/0000-0003-1794-5951
Yoon, Hong In(윤홍인) ORCID logo https://orcid.org/0000-0002-2106-6856
Jung, Inkyung(정인경) ORCID logo https://orcid.org/0000-0003-3780-3213
Han, Kwang-Hyub(한광협) ORCID logo https://orcid.org/0000-0003-3960-6539
사서에게 알리기


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.